Study of aetiology, clinical profile and B-type natriuretic peptide levels in heart failure with preserved and reduced ejection fraction

https://doi.org/10.53730/ijhs.v6nS8.13704

Authors

  • Sunil Kumar Associate Professor, Department of General medicine, SBKS MIRC, Sumandeep Vidyapeeth, Vadodara
  • Jeevana Sudha Ande Resident, Department of General medicine, SBKS MIRC, Sumandeep Vidyapeeth, Vadodara
  • Vidhi Shah Resident, Department of General medicine, SBKS MIRC, Sumandeep Vidyapeeth, Vadodara
  • Shaival Trivedi Associate Professor, Department of general medicine, SBKS MIRC, Vadodara

Keywords:

aetiology, clinical profile, B-type natriuretic peptide levels, heart failure

Abstract

Since from the last one decade, new cardiac biomarkers specifically BNP levels are being used widely as a marker of diagnosis, severity and prognosis of HF. A Cross Sectional Study was conducted at Department Of General Medicine, Dhiraj Hospital, Sbks MIRC, Pipariya, Vadodara with a sample size of 70. A total of 70 patients with heart failure were studied and found that 41 (58.57%) patients had reduced ejection fraction and 29 (41.43%) patients had preserved ejection fraction. In our study majority of the patients were found in NYHA Grade IV (37.14). The mean BNP levels of the whole study group is 1148.73±876.61. The mean level of BNP in HFpEF is 905.28± 823.73 and in HFrEF is 1320.93 ± 881.60. There was statistically significant difference was observed in between the two groups (p value P = 0.0499). In our present study the BNP levels are increasing with increasing NYHA severity of breathlessness (p= 0.0113). The study showed as the severity of NYHA grading increases the BNP levels increase. BNP levels tend to increase more in hypertensive patients as compared to non hypertensive patients. 

Downloads

Download data is not yet available.

References

Douglas. L. Mann, Murali Chakinala. Heart Failure: Pathophysiology and Diagnosis. Harrison's Principles of Internal Medicine 20th Edition; vol (2), sec 4 (252),1763,1764.

K. Yamamoto, M.M. Redfield, R.A. Nishimura.Analysis of left ventricular diastolic function.Heart, 75 (Suppl 2) (1996), pp. 27-35.

Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study. Journal of the American College of Cardiology. 2003 Jun 4;41(11):2010-7.

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. New Engl J Med. 2008;359:2456–2467.

R.S. Vasan, D. Levy.Defining diastolic heart failure: a call for standardized diagnostic criteria.Circulation, 101 (2000), pp. 2118-2121.

T. Masuyama, R.L. Popp.Doppler evaluation of left ventricular filling in congestive heart failure.Eur Heart J, 18 (1997), pp. 1548-1556.

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781.

Published

30-11-2022

How to Cite

Kumar, S., Ande, J. S., Shah, V., & Trivedi, S. (2022). Study of aetiology, clinical profile and B-type natriuretic peptide levels in heart failure with preserved and reduced ejection fraction. International Journal of Health Sciences, 6(S8), 6046–6053. https://doi.org/10.53730/ijhs.v6nS8.13704

Issue

Section

Peer Review Articles

Most read articles by the same author(s)